PS1265 IMPROVEMENTS IN OUTCOME OF MANTLE‐CELL LYMPHOMA (MCL) ARE MOSTLY DUE TO ADVANCES IN INDUCTION THERAPY AND AUTOLOGOUS STEM‐CELL TRANSPLANTATION (ASCT) – A REAL‐LIFE NON‐INTERVENTIONAL STUDY OF KROHEM

• Published in: HemaSphere 2019-06, Vol.3 (S1), p.579-n/a
• Main Authors: Aurer, I., Misura‐Jakobac, K., Sincic‐Petricevic, J., Deak, D., Vodanovic, M., Jakic‐Bubalo, M., Mitrovic, Z., Grubesic, A., Dreta, B., Zupanic‐Krmek, D., Coha, B.
• Format: Article
• Language: English
• ISSN: 2572-9241; 2572-9241
• DOI: 10.1097/01.HS9.0000563340.44346.69

Background: Outcome of patients with newly diagnosed MCL has improved substantially in the last decade. This coincided with the more frequent use of high‐dose cytarabine (HD‐AraC) and bendamustine (B) containing induction regimens, ASCT in first remission and rituximab (R) maintenance. Some real‐life studies suggested that the latter was most important. Aims: KroHem, the Croatian Cooperative Group for Hematologic Diseases initiated this study to analyze outcomes of patients with MCL who started treatment or were diagnosed between 2015 and 2017 (recent cohort), identify prognostic factors and compare the results to those of a historical cohort who started treatment between 2007 and 2008. Methods: This was a retrospective study including all patients with MCL fulfilling the entry criteria seen at participating centers during the defined periods. Results: In the recent cohort 83 patients were treated, 2 received supportive care only and 5 had indolent disease and were observed. Median age was 68, 68% were male. All 40 patients in the historical cohort were treated, their median age was 67, 70% were male. All treated patients received R. Median follow up of the recent cohort was 20 mo and of the historical 39 mo. 2‐year overall survival (OS) of treated patients increased from 57% to 81% and 2‐year event free survival (EFS) from 41% to 57%. None of the indolent MCL patients progressed. MIPI, age and cytology were significant prognostic factors in the recent cohort for OS (p values 0.006, 0.006 and 0.013 respectively) and EFS (p values 6 mo received ASCT compared to 12.5% in the historical; outcome of transplanted patients was similar (2‐year EFS 83% vs. 80%). In the recent cohor